TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22200382

Group type: EXPERIMENTAL
Intervention: Evidence-based conservative care (protocol of care)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual conservative care
Number of subjects: 118
Study: 21047590

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing every 4 years)
Number of subjects: 182160

Group type: COMPARATOR
Intervention: Control arm (usual care)
Number of subjects: 182160
Study: 18321010

Group type: EXPERIMENTAL
Intervention: Vignette with high intimacy relationship history
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Vignette with medium intimacy relationship history
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Vignette with low intimacy relationship history
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 414

Group type: COMPARATOR
Intervention: Women
Number of subjects: 414
Study: 15653117

Group type: EXPERIMENTAL
Intervention: Xuezhikang 1200 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Xuezhikang 2400 mg/day
Number of subjects: 48
Study: 12121726

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 103
Study: 10554570

Group type: EXPERIMENTAL
Intervention: Detection of ICA antibodies
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Detection of anti-GAD antibodies
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Detection of IA-2 antibodies
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Presence of 2 types of antibodies
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Birth weight of children
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Previous pregnancies
Number of subjects: 156
Study: 8904364

Group type: EXPERIMENTAL
Intervention: Laptop computers with 9 hours of computer instruction
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual manner of completing assignments (comparison group)
Number of subjects: 38
Study: 2000923

Group type: EXPERIMENTAL
Intervention: Futuro prefabricated wrist brace (No. 33)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Volar thumbhole orthosis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Volar orthosis with radial connector bar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dorsal orthosis with distal transverse arch support
Number of subjects: 20

Group type: COMPARATOR
Intervention: All orthoses
Number of subjects: 20
Study: 6640248

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 30712687

Group type: EXPERIMENTAL
Intervention: Part-time wear of Twin-block appliance (12 hours daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Full-time wear of Twin-block appliance (22 hours daily)
Number of subjects: 62
Study: 28323044

Group type: EXPERIMENTAL
Intervention: Medium doses of vitamin D (1600, 2400, 3200 IU)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low doses of vitamin D (400, 800 IU)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High doses of vitamin D (4000, 4800 IU)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Serum 25OHD quintiles
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Subgroup with a fall history
Number of subjects: 7
Study: 27267679

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 120
Study: 24820858

Group type: EXPERIMENTAL
Intervention: 500 mg ginger, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo, two times per day, 30 min before each dose of antiretroviral regimen for 14 days
Number of subjects: 102
Study: 22721261

Group type: COMPARATOR
Intervention: Curtin University's Activity, Food and Attitudes Program (CAFAP), an 8-week intensive multidisciplinary program with follow-up assessments at 3, 6, and 12 months.
Number of subjects: 96
Study: 19878784

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) imaging
Number of subjects: 496

Group type: COMPARATOR
Intervention: Computed tomography (CT) imaging
Number of subjects: 496

Group type: COMPARATOR
Intervention: CDU imaging vs CT imaging
Number of subjects: 496
Study: 18158045

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15079005

Group type: EXPERIMENTAL
Intervention: Tetanic contractions evoked by 10-Hz ulnar nerve stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twitch contractions evoked by single ulnar nerve stimulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tetanic RT (90 to 5%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Twitch RT (90 to 5%)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Correlation of RT with leukocyte CTG repeat length
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test-retest variability for tetanic RT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test-retest variability for tetanic PF
Number of subjects: 30
Study: 10580169

Group type: EXPERIMENTAL
Intervention: N-monomethyl-L-arginine (LNMMA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9357351

Group type: EXPERIMENTAL
Intervention: Telephone help line plus active telephone outreach
Number of subjects: 509

Group type: COMPARATOR
Intervention: Group session without telephone support
Number of subjects: 509

Group type: COMPARATOR
Intervention: Session plus access to a toll‐free help line
Number of subjects: 509
Study: 8174950

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg twice daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 66
Study: 3515333

Group type: EXPERIMENTAL
Intervention: Oral naproxen (250 mg per day for two weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Local injection of betamethasone (6 mg in a long-acting form)
Number of subjects: 21
Study: 2893916

Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: digoxin 0.125 mg twice daily
Number of subjects: 433

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: xamoterol
Number of subjects: 433
Study: 30737610

Group type: EXPERIMENTAL
Intervention: Voluntary Medical Male Circumcision (VMMC) services in 2014/15
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voluntary Medical Male Circumcision (VMMC) services in 2013
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Awareness of circumcision benefits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived service availability in 2013
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived service availability in 2014/15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of knowledge of prevention tools
Number of subjects: 0
Study: 27871030

Group type: EXPERIMENTAL
Intervention: Body psychotherapy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Pilates
Number of subjects: 275
Study: 26372401

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) administered after each of 10 CBT sessions
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (PBO) administered after each of 10 CBT sessions
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) with high homework compliance
Number of subjects: 27
Study: 23953385

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 7243
Study: 21397483

Group type: EXPERIMENTAL
Intervention: Formoterol (12 μg, twice daily for 14 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 μg, once daily for 14 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single dose of Formoterol (200 μg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single dose of Tiotropium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single dose of Salbutamol (200 μg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18344753

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Unoprostone 0.15%
Number of subjects: 115

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 115
Study: 16586424

Group type: EXPERIMENTAL
Intervention: Dual-contrast (DC) cluster analysis
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Scout geometry (SG) algorithm
Number of subjects: 21
Study: 14531243

Group type: EXPERIMENTAL
Intervention: Internet-based store-and-forward video home telehealth system
Number of subjects: 10

Group type: COMPARATOR
Intervention: In-person asthma education
Number of subjects: 10

Group type: COMPARATOR
Intervention: Interactive Web site asthma education
Number of subjects: 10
Study: 10700672

Group type: EXPERIMENTAL
Intervention: BUD Turbuhaler 600 microg qid
Number of subjects: 185

Group type: COMPARATOR
Intervention: PRED 40 mg in the morning
Number of subjects: 185
Study: 9596864

Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.100 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.125 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 15‐methyl‐PGF2 alpha 0.200 mg
Number of subjects: 150
Study: 8404386

Group type: EXPERIMENTAL
Intervention: Transproctoscopic Doppler ultrasound followed by local injection treatment with 5 percent phenol almond oil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional sclerotherapy without Doppler investigation
Number of subjects: 80
Study: 2948853

Group type: EXPERIMENTAL
Intervention: RA27/3 rubella vaccine from Institut Merieux
Number of subjects: 231

Group type: COMPARATOR
Intervention: RA27/3 rubella vaccine from Wellcome
Number of subjects: 231
Study: 31881096

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Detached Mindfulness (DM)
Number of subjects: 39
Study: 28866765

Group type: EXPERIMENTAL
Intervention: eReCog program (4-week duration, comprised of four online modules)
Number of subjects: 60
Study: 28545277

Group type: EXPERIMENTAL
Intervention: Ischemic post-conditioning (IPC)
Number of subjects: 251
Study: 26242331

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 10,000 i.u. for 7 consecutive days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no Epo treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 42
Study: 23870654

Group type: EXPERIMENTAL
Intervention: Supervised balance exercises (six 1-hour circuit classes)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Usual-care control group (standard rehabilitation intervention including physiotherapy mobility training and exercise for at least two hours on each weekday)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Supervised balance exercises
Number of subjects: 162
Study: 21355659

Group type: EXPERIMENTAL
Intervention: Newly developed scale measuring identity fusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Earlier pictorial measure of identity fusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Verbal fusion scale (Spanish and English versions)
Number of subjects: 10
Study: 18493215

Group type: EXPERIMENTAL
Intervention: whey-based formula with galacto- and long-chain fructo-oligosaccharides (scGOS/lcFOS group)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: whey-based formula with galacto- and long-chain fructo-oligosaccharides added with pectin-derived acidic oligosaccharides (scGOS/lcFOS/pAOS group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: whey-based formula (control group)
Number of subjects: 82
Study: 16841269

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectopexy (surgical procedure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historic control study
Number of subjects: 0
Study: 14631699

Group type: EXPERIMENTAL
Intervention: Cook Osteo-site needle
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cook Paediatric Intraosseus Insertion needle
Number of subjects: 16
Study: 10772190

Group type: EXPERIMENTAL
Intervention: Small-bore nasogastric tube (NGT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No small-bore nasogastric tube (NGT)
Number of subjects: 30
Study: 9353404

Group type: EXPERIMENTAL
Intervention: Formoterol (120 microg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8412310

Group type: EXPERIMENTAL
Intervention: Continuous infusion carboplatin 250 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous infusion carboplatin 310 mg/m2 per day for 5 days and etoposide 150 mg/m2 per day for 5 days.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 32
Study: 2874032

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 31411963

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) plus prednisone
Number of subjects: 1082

Group type: COMPARATOR
Intervention: Prednisone (Control)
Number of subjects: 1082
Study: 29161204

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with carboplatin plus paclitaxel and 41.4-Gy radiotherapy followed by surgery
Number of subjects: 363

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 363
Study: 29691557

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser combined with AdperTM Easy One
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nd:YAG laser combined with AdperTM Easy One
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 25759746

Group type: EXPERIMENTAL
Intervention: Yoga practice (1.5 hours per day, 6 days a week for 5 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 23796235

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 394

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 394
Study: 20683035

Group type: EXPERIMENTAL
Intervention: saracatinib 500 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: saracatinib 125 mg for 14 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 17702667

Group type: EXPERIMENTAL
Intervention: Instrumented paper diaries (IPDs) used for self-monitoring during an 18-month weight-loss program.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-reported data on diary usage.
Number of subjects: 64
Study: 16649859

Group type: EXPERIMENTAL
Intervention: Anger hypothesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivated reasoning hypothesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group differentiation hypothesis
Number of subjects: 0
Study: 12680790

Group type: EXPERIMENTAL
Intervention: Surgery for solitary metastasis in operable location and symptomatic mass effect
Number of subjects: 0

Group type: COMPARATOR
Intervention: WBRT (Whole Brain Radiation Therapy) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WBRT + SRS (Stereotactic Radiosurgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRS alone
Number of subjects: 0
Study: 10639613

Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Progressive home exercise program
Number of subjects: 100
Study: 8904876

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) coupled to hydroxyethyl starch (HES-DFO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-Tf receptor antibody 42/6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron repletion by haemin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron chelation with DFO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blockade of Tf-mediated iron uptake with anti-Tf receptor antibody 42/6
Number of subjects: 0
Study: 1652265

Group type: EXPERIMENTAL
Intervention: pH-adjusted solution of 2% mepivacaine with epinephrine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard commercial preparation of 2% mepivacaine with epinephrine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study: 7055082

Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.4 ppm O3
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2 plus 0.4 ppm O3
Number of subjects: 8

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 8
Study: 31823433

Group type: EXPERIMENTAL
Intervention: GO blended RelyX (RXGO)
Number of subjects: 12

Group type: COMPARATOR
Intervention: RelyX (RX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Monobond-S (MB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GO blended Monobond-S (MBGO)
Number of subjects: 12
Study: 28993335

Group type: EXPERIMENTAL
Intervention: Efavirenz in combination with Zidovudine-Lamivudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maraviroc in combination with Zidovudine-Lamivudine
Number of subjects: 0
Study: 25988766

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES) 3mL·kg(‐1) body mass of a 6% CES every 20 min during exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo drink (PL) every 20 min during exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo drink (PL)
Number of subjects: 8
Study: 23681159

Group type: EXPERIMENTAL
Intervention: Smoking as usual
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overnight abstinence from smoking
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Reward trial blocks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: No-reward trial blocks
Number of subjects: 25
Study: 21440749

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC; 4-6 ng/mL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL; 6-10 ng/mL)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (TAC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 58
Study: 19811343

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16924980

Group type: EXPERIMENTAL
Intervention: Nanofilled resin composite (Filtek Supreme)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Microhybrid composite (Pyramid, Esthet‐X, Tetric Ceram)
Number of subjects: 42
Study: 15868872

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue fixation
Number of subjects: 213
Study: 11704395

Group type: EXPERIMENTAL
Intervention: 100 mg eniporide
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: 150 mg eniporide
Number of subjects: 1389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Overall eniporide treatment
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Late reperfusion (>4 h)
Number of subjects: 1389
Study: 9462186

Group type: EXPERIMENTAL
Intervention: Synthetic triglyceride milk formula containing Betapol with 74% palmitate in the 2-position
Number of subjects: 24
Study: 7481086

Group type: EXPERIMENTAL
Intervention: Fair Play for Kids curriculum during physical education only
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Fair Play for Kids curriculum during all school subjects
Number of subjects: 452

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 452
Study: 2184847

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 820

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 820
Study: 7191310

Group type: EXPERIMENTAL
Intervention: Acemetacin (3 x 30 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Indometacin (3 x 50 mg/d)
Number of subjects: 40
Study: 30606140

Group type: EXPERIMENTAL
Intervention: Systematic risk assessment during pregnancy with emphasis on identification of non‐medical risk factors and client‐tailored approach during pregnancy and postpartum.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Systematic risk assessment during pregnancy only.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Client-tailored approach during pregnancy and postpartum.
Number of subjects: 12
Study: 27749321

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg/day vs 20 mg/day
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Atorvastatin administration
Number of subjects: 198
Study: 26407654

Group type: EXPERIMENTAL
Intervention: Perindopril 5mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Barnidipine 20mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Barnidipine 20mg/day + Simvastatin 20mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Perindopril 5mg/day + Simvastatin 20mg/day
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg/day (added to both treatments)
Number of subjects: 149
Study: 23943839

Group type: EXPERIMENTAL
Intervention: Heaviness of Smoking Index (HSI)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Salivary cotinine
Number of subjects: 1050
Study: 22288485

Group type: EXPERIMENTAL
Intervention: FMUD+AM (375 mg amoxicillin plus 250 mg metronidazole for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: FMUD (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FMUD+AM
Number of subjects: 24

Group type: COMPARATOR
Intervention: FMUD
Number of subjects: 24
Study: 20670329

Group type: EXPERIMENTAL
Intervention: Peer-conducted motivational intervention with a 10-day booster
Number of subjects: 853

Group type: COMPARATOR
Intervention: Standard assessed control (AC)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Minimally assessed control (MAC)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Both I and AC groups
Number of subjects: 853